Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1481-1500 of 1,694 trials

DAVINCY Trial: (fos)Aprepitant for Nausea in Children

We are studying whether a longer duration of (fos)aprepitant can better prevent nausea and vomiting in children receiving chemotherapy. This trial compares the standard treatment with an extended regimen to find the most effective approach.

Delayed Chemotherapy Induced Nausea and VomitingConfirmation phase (III)Investigational MedicinesPartially RemoteInternal MedicineOncologyPediatrics

Prostate Cancer: Atorvastatin Study

We are investigating whether atorvastatin can help delay prostate cancer progression in men receiving androgen deprivation therapy. This study aims to see if it can prevent the cancer from becoming resistant to treatment.

Metastatic Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesOncologyUrology

ADPKD Treatment: Metformin vs. Tolvaptan

We are studying whether Metformin can effectively slow kidney function decline in adults with Autosomal Dominant Polycystic Kidney Disease compared to Tolvaptan. The trial also examines the safety and impact on kidney size and symptoms.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Nephrotic Syndrome: Ketoanalogues for Muscle Preservation

We are studying a new treatment to help prevent muscle loss in patients with nephrotic syndrome. This trial will assess its safety and how it may improve overall health and quality of life.

Protein-Energy Wasting in Nephrotic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Kidney Health After Transplant: Dapagliflozin Study

We are studying how dapagliflozin affects kidney structure and inflammation in patients with impaired kidney function one year after transplantation. This research may help us understand better treatments for kidney transplant recipients.

Chronic Kidney Disease (CKD)3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Atherosclerosis: Psilocybin Therapy Study

We are exploring if psilocybin-assisted therapy can help reduce plaque buildup in patients with ischemic heart disease. This study will also look at safety and changes in plaque characteristics over time.

Stable Ischemic Heart DiseaseEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Autoimmune Uveitis: Probiotic Supplement Study

We are studying the effects of a probiotic on people with autoimmune uveitis to see if it improves vision and reduces inflammation. The trial will also check the safety of this treatment.

Autoimmune Uveitis1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOphthalmology

Alzheimer’s Disease: NTRX-07 Treatment Study

We are investigating the safety and tolerability of NTRX-07 in people with mild cognitive impairment or mild to moderate Alzheimer's disease. This study aims to understand how well the treatment works and its effects on patients.

Mild Cognitive Impairment (MCI)Mild to Moderate Alzheimer's Disease (AD)≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Leukemia Treatment: Ponatinib vs. Imatinib

We are studying whether ponatinib combined with chemotherapy is as effective as imatinib for adults with Philadelphia-Chromosome positive acute lymphoblastic leukemia. The trial also evaluates treatment outcomes for patients who respond differently.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Warm Autoimmune Hemolytic Anemia: Rilzabrutinib Study

We are investigating whether the oral medication rilzabrutinib can improve hemoglobin levels and reduce symptoms in adults with warm autoimmune hemolytic anemia. This study will also assess its safety compared to a placebo.

Autoimmune Hemolytic Anemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesHematologyInternal Medicine

Essential Tremor: BP1.4979 Treatment Study

We are testing a new medication, BP1.4979, for adults with essential tremor to see if it helps reduce symptoms and improve quality of life. The study will also check how safe the treatment is for patients.

Essential Tremor1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Premature Ejaculation: BP1.4979 Study

We are testing a new medication for adult men with primary premature ejaculation to see if it improves ejaculatory control and sexual satisfaction compared to a placebo.

Premature Ejaculation3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryUrology

Turner Syndrome: Estrogen Therapy Comparison

We are studying the long-term effects of oral versus transdermal estrogen replacement therapy in women with Turner syndrome. This research aims to clarify health risks and benefits associated with each treatment method.

Turner's Syndrome6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Prostate Cancer: Ebastine with Docetaxel or Cabazitaxel

We are studying a new treatment combining ebastine with either docetaxel or cabazitaxel for men with metastatic castration-resistant prostate cancer. The goal is to evaluate how this combination affects cancer markers and PSA levels.

Hormone-Refractory Prostate Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Schizophrenia: Cariprazine for Cognitive Function

We are studying how cariprazine affects cognitive functioning in patients with schizophrenia who need changes to their current treatment. The trial will also look at overall quality of life and any side effects.

Acute Schizophrenia6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Cardiac Arrest and Ventricular Fibrillation: RIME-IVF Study

We are investigating how beta-blocker treatment affects patients with idiopathic ventricular fibrillation and those who have had out-of-hospital cardiac arrests. We also aim to understand the quality of life for survivors of cardiac arrest.

Idiopathic Ventricular FibrillationMonitoring phase (IV)No PlaceboStandard MedicinesCardiology

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

We are studying whether a high dose of psilocybin can help reduce heavy drinking in people with severe alcohol use disorder during inpatient rehabilitation. This trial also examines the safety and effects on mental health and cognitive function.

Severe Alcohol Use Disorder6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPsychiatry

Acute Myeloid Leukemia: Eganelisib Treatment Study

We are studying the safety and tolerability of eganelisib alone and with cytarabine in patients with relapsed or refractory acute myeloid leukemia. This trial aims to find the best dose and evaluate how well the treatment works.

Relapsed/Refractory Acute Myeloid LeukemiaHigher-Risk Myelodysplastic SyndromesSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Locally Advanced Rectal Cancer: FOLFOX Before Surgery

We are comparing the effects of chemotherapy before surgery to risk-adapted chemotherapy after surgery for patients with locally advanced rectal cancer. Our goal is to see which approach may lead to better disease-free survival and fewer complications.

Locally Advanced Rectal Cancer≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Lung Cancer: RMC-6236 vs. Docetaxel

We are studying a new treatment for patients with advanced lung cancer who have RAS mutations. The goal is to see if RMC-6236 works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology